Event Title
Combination of Pim kinase inhibitors with Bcl-2 antagonist in Chronic Lymphocytic Leukemia
Co-investigators
Fabiola Gomez and Varsh a Gandhi, University of Texas MD Anderson Cancer Center
Faculty Mentor
Curt Phifer
Location
Library 3B
Session
Session 2
Start Date
13-4-2013 11:00 AM
End Date
13-4-2013 12:00 PM
Description
In chronic lymphocytic leukemia (CLL), the intrinsic pathway, which leads to the death of normal lymphocytes, is blocked by overexpression of anti-apoptotic Bcl-2 family proteins and Pim kinases. Blocking both of these anti-apoptotic molecules should allow pro-apoptotic proteins to function normally, causing cancerous cells to die. ABT-737, a drug currently in clinical trials, antagonizes Bcl-2 but by itself does not induce considerable cell death. In this project, ABT-737 and a Pim kinase inhibitor were used in combination against isolated CLL cells. Although the combined agents induced greater CLL cell death than either alone, the effects were not additive or synergistic.
Combination of Pim kinase inhibitors with Bcl-2 antagonist in Chronic Lymphocytic Leukemia
Library 3B
In chronic lymphocytic leukemia (CLL), the intrinsic pathway, which leads to the death of normal lymphocytes, is blocked by overexpression of anti-apoptotic Bcl-2 family proteins and Pim kinases. Blocking both of these anti-apoptotic molecules should allow pro-apoptotic proteins to function normally, causing cancerous cells to die. ABT-737, a drug currently in clinical trials, antagonizes Bcl-2 but by itself does not induce considerable cell death. In this project, ABT-737 and a Pim kinase inhibitor were used in combination against isolated CLL cells. Although the combined agents induced greater CLL cell death than either alone, the effects were not additive or synergistic.